• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by MaxCyte Inc.

    3/27/26 10:34:15 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MXCT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    MaxCyte Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    57777K106

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    57777K106


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    MaxCyte Inc
    (b)Address of issuer's principal executive offices:

    22 Firstfield Road, Suite 110, Gaithersburg, MD, 20878
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/27/2026
    Get the next $MXCT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MXCT

    DatePrice TargetRatingAnalyst
    8/11/2025Buy → Neutral
    BTIG Research
    8/7/2025Outperform → Mkt Perform
    William Blair
    7/22/2025$6.00Overweight
    Stephens
    11/29/2023$7.00Buy
    Craig Hallum
    10/15/2021Outperform
    Cowen
    8/24/2021$36.00Outperform
    Wedbush
    8/24/2021Outperform
    William Blair
    8/24/2021$19.00Overweight
    Stephens
    More analyst ratings

    $MXCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

    Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md., March 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform

    3/24/26 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

    ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. "Parmeet is an exceptionally talented finance leader whose experience and expertise position him well to strengthen MaxCyte's financial operations," said Maher Masoud, Chief Executive Officer. "His deep background in

    3/23/26 8:05:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery

    ROCKVILLE, Md., Feb. 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the launch of ExPERT DTx™, a new high throughput transfection platform for research and drug discovery applications. This modular, 96-well electroporation system enables labs to transfect primary cells and cell lines with minimal cellular stress, helping researchers to uncover valuable insights and better understand fundamental biological processes before scaling up to larger transfection volumes. ExPERT DTx stream

    2/24/26 8:05:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MaxCyte downgraded by BTIG Research

    BTIG Research downgraded MaxCyte from Buy to Neutral

    8/11/25 9:48:40 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte downgraded by William Blair

    William Blair downgraded MaxCyte from Outperform to Mkt Perform

    8/7/25 7:35:46 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Stephens initiated coverage on MaxCyte with a new price target

    Stephens initiated coverage of MaxCyte with a rating of Overweight and set a new price target of $6.00

    7/22/25 7:53:47 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Swirsky Douglas J

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    3/19/26 4:05:29 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Hemrajani Rekha sold $22,378 worth of shares (10,684 units at $2.09), decreasing direct ownership by 21% to 39,893 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/27/25 5:12:01 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    CHIEF FINANCIAL OFFICER Swirsky Douglas J bought $64,500 worth of shares (50,000 units at $1.29), increasing direct ownership by 45% to 161,811 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:48:49 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    SEC Filings

    View All

    MaxCyte Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - MAXCYTE, INC. (0001287098) (Filer)

    3/27/26 4:54:45 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by MaxCyte Inc.

    SCHEDULE 13G/A - MAXCYTE, INC. (0001287098) (Subject)

    3/27/26 10:34:15 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 10-K filed by MaxCyte Inc.

    10-K - MAXCYTE, INC. (0001287098) (Filer)

    3/25/26 4:36:25 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF FINANCIAL OFFICER Swirsky Douglas J bought $64,500 worth of shares (50,000 units at $1.29), increasing direct ownership by 45% to 161,811 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:48:49 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    President and CEO Masoud Maher bought $102,915 worth of shares (75,000 units at $1.37), increasing direct ownership by 75% to 175,000 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:47:52 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Erck Stanley C bought $137,220 worth of shares (100,000 units at $1.37), increasing direct ownership by 34% to 398,328 units (SEC Form 4)

    4 - MAXCYTE, INC. (0001287098) (Issuer)

    8/13/25 7:47:13 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    Leadership Updates

    Live Leadership Updates

    View All

    MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

    ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ:MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025. "Parmeet is an exceptionally talented finance leader whose experience and expertise position him well to strengthen MaxCyte's financial operations," said Maher Masoud, Chief Executive Officer. "His deep background in

    3/23/26 8:05:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO

    Industry veteran brings two decades of platform commercialization experience in cell therapy, bioprocessing, and bioanalytics as Cellares prepares to support multiple clinical trials in 2026 Appointment follows five global manufacturing agreements with partners, including Bristol Myers Squibb, Kite, and leading academic institutions, as well as the FDA's first Advanced Manufacturing Technology designation for a cell therapy manufacturing platform. Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer. Soleymannezhad, formerly Chief Commercial Officer at MaxCyte (NASDAQ:MXCT) an

    12/1/25 9:00:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

    ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT)), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced the completion of an internal operational review, initiated earlier this year following the appointment of Maher Masoud as President and Chief Executive Officer. This "bottom-up" review focused on optimizing new product development, manufacturing, commercial execution, and capital allocation to enhance efficiency and align resources with strategic priorities. As part of an effort to streamline operations,

    12/9/24 2:00:00 AM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    Financials

    Live finance-specific insights

    View All

    MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

    Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in total cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md., March 24, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform

    3/24/26 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026

    ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the fourth quarter and full year 2025 after the U.S. market close on Tuesday, March 24th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time. Earnings Conference Call DetailsInvestors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advanc

    2/23/26 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance

    ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its third quarter ended September 30, 2025 financial results and reiterated its 2025 guidance. Third Quarter and Recent Highlights Core business revenue of $6.4 million in the third quarter of 2025.Strategic Platform License SPL Program-related revenue was $0.4 million for the third quarter of 2025.Total revenue of $6.8 million in the third quarter of 2025.MaxCyte added one new SPL client, Moonlight Bio, in Octobe

    11/12/25 4:05:00 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $MXCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MaxCyte Inc.

    SC 13G/A - MAXCYTE, INC. (0001287098) (Subject)

    11/13/24 7:14:35 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by MaxCyte Inc.

    SC 13G/A - MAXCYTE, INC. (0001287098) (Subject)

    10/31/24 4:23:48 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G filed by MaxCyte Inc.

    SC 13G - MAXCYTE, INC. (0001287098) (Subject)

    3/25/24 4:36:08 PM ET
    $MXCT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care